MVD1 / Eolo Pharma - LARVOL DELTA

A Phase 1, Randomised, Double-blind, Placebo-controlled, First in Human Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of MVD1 in Normal Weight or Overweight Healthy Adult Volunteers and Multiple Doses of MVD1 in Overweight or Obese Healthy Adult Volunteers (ANZCTR) - P1 | N=42 | Completed | Sponsor: Eolo Pharma Pty Ltd | Recruiting ➔ Completed

First-in-human • Trial completion • Genetic Disorders • Metabolic Disorders • Obesity • LEP